Skip to main content
. 2015 Apr 22;58(4):123–128. doi: 10.3345/kjp.2015.58.4.123

Fig. 4. The Korea Cancer Center Hospital data: comparison of the overall survival (OS) of patients receiving gemcitabine and docetaxel (GEMDOC) chemotherapy as adjuvant or palliative therapy. OS was determined from the start of GEMDOC chemotherapy to death from any cause.

Fig. 4